The Patent Finder
AT

Aldeyra Therapeutics, Inc.

First filing 2006
OverviewNotableFeesChangesFamiliesPatent listSources & methods

Previously recorded as Neuron Systems, Inc. (to 2013)

35 patents currently held

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
1 more record may belong here and awaits a decision; it is not counted.

The next term ends in Jan 2027. from the record

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
4
Ending by 2030
Jan 2027
Next term end
18
Patent families

When these terms end

Held patents by the year their term ends
notable patents fee due within 90 days all others Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Toxic Aldehyde Related Diseases and Treatment US 11,701,331
Cited by 17 later US patents, top 5% of utility patents granted in 2023 in our data. Protection runs to 2034.
Ends Jan 2034 · Medium confidence
Also notable
Deuterated Compounds and Uses Thereof US 11,459,300
Cited by 20 later US patents, top 5% of utility patents granted in 2022 in our data. Protection runs to 2036.
Ends Aug 2036 · High confidence
Also notable
Compositions and Methods of Treating Retinal Disease US 8,940,721
Cited by 55 later US patents, top 10% of utility patents granted in 2015 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2027. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
Ends no later than Jan 2027 · Medium confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Jan 18, 2027
    The maintenance fee for Toxic Aldehyde Related Diseases and Treatment (US 11,701,331) comes due Jan 18, 2027. Unpaid by Jul 19, 2027, it lapses early.
  • 1 fee due Mar 17, 2027
    The maintenance fee for Polymorphic Compounds and Uses Thereof (US 10,414,732) comes due Mar 17, 2027. Unpaid by Sep 17, 2027, it lapses early.
  • 3 fees due Apr 1 to 17, 2027 · next Apr 1
  • 1 fee due Jun 19, 2027
    The maintenance fee for Deuterated Compounds and Uses Thereof (US 11,845,722) comes due Jun 19, 2027. Unpaid by Dec 20, 2027, it lapses early.
  • 1 fee due Jul 28, 2027
    The maintenance fee for Toxic Aldehyde Related Diseases and Treatment (US 10,543,181) comes due Jul 28, 2027. Unpaid by Jan 28, 2028, it lapses early.
  • 2 fees due Aug 4 to 27, 2027 · next Aug 4
  • 1 fee due Sep 17, 2027
    The maintenance fee for Toxic Aldehyde Related Diseases and Treatment (US 10,588,874) comes due Sep 17, 2027. Unpaid by Mar 17, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 1 term has ended since Aug 23, 2026

What they patent

The largest of its 18 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.

Patents held now

Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatusExpiresConfidence
US 8,940,721Compositions and Methods of Treating Retinal Disease
In force
 · Medium confidence
In forceMedium confidence
US 7,973,025Compositions and Methods of Treating Retinal Disease
In force
 · High confidence
In forceHigh confidence
US 8,940,764Compositions and methods of treating retinal disease
In force
 · High confidence
In forceHigh confidence
US 12,097,188Compositions and Methods for the Treatment of Macular Degeneration
In force
 · High confidence
In forceHigh confidence
US 9,814,701Compositions and Methods for the Treatment of Macular Degeneration
In force
 · High confidence
In forceHigh confidence
US 9,604,997Peri-Carbinols
In force
 · High confidence
In forceHigh confidence
US 9,687,481Toxic Aldehyde Related Diseases and Treatment
In force
 · High confidence
In forceHigh confidence
US 10,213,395Toxic Aldehyde Related Diseases and Treatment
In force
 · High confidence
In forceHigh confidence
US 10,543,181Toxic Aldehyde Related Diseases and Treatment
In force
 · High confidence
In forceHigh confidence
US 10,588,874Toxic Aldehyde Related Diseases and Treatment
In force
 · Medium confidence
In forceMedium confidence
10 of 35 patents shown.
Pro members see all 35.
Pro members: see all 35 patents
Also on record, not counted in the 35: 8 patents ended · 9 applications pending · 18 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited